Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of Localised Pancreatic Adenocarcinoma Following Preoperative (m)FOLFIRINOX By Ogkologos - March 11, 2025 530 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR The most important cancer research stories of 2022 December 14, 2022 FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection October 2, 2024 FDA Grants Traditional Approval to Selpercatinib for RET Fusion-positive Thyroid Cancer July 2, 2024 For People with Cancer, Are Steroids the Best Treatment for Breathing... October 25, 2022 Load more HOT NEWS For Women Returning from Breast Cancer Treatment, Work Often Changes Involuntarily Regular Aspirin Use May Increase Older People’s Risk of Dying from... A College Senior vs. A Global Pandemic Expectant Mom with “Blocked Milk Duct” Discovers She Has Cancer at...
